Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
Myelodysplastic syndromes (MDS) are a heterogeneous clonal disease of myeloid neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and an increased risk of progression to acute ...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Razan Mohty, Rama Al Hamed, Ali Bazarbachi, Eolia Brissot, Arnon Nagler, Amer Zeidan and Mohamad Mohty Tags: Review Source Type: research